Drug Dev
Europe needs more patient capital to nurture biotechs
Analysis by the European Investment Bank predicts that EU biotechs face a funding shortfall of up to EUR 40 billion by 2021. Barbara Freischem, executive director of European Biopharmaceutical Enterprises, who moderated a panel on the topic at BIO-Europe Spring 2018, talked to Scrip about how initiatives that could alleviate the shortfall.